About NextFerm
NextFerm is a company based in Yokneam Illit (Israel) founded in 2013. NextFerm offers products and services including ProteVin™, Maximmune, AstaFerm®, NextFreeze™, and Biofuel. NextFerm operates in a competitive market with competitors including Nuevolution, Protalix BioTherapeutics, Lutris Pharma, Curesponse and Colbar LifeScience, among others.
- Headquarter Yokneam Illit, Israel
-
Sectors
HealthcareAgriculture
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nextferm Technologies
-
Annual Revenue
$176.63 K (USD)-38.29as on Dec 31, 2024
-
Net Profit
-$5.4 M (USD)-25.43as on Dec 31, 2024
-
EBITDA
-$3.62 M (USD)5.73as on Dec 31, 2024
-
Latest Funding Round
$55.99 K (USD), Grant
Dec 31, 2019
-
Investors
European Union
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of NextFerm
NextFerm offers a comprehensive portfolio of products and services, including ProteVin™, Maximmune, AstaFerm®, NextFreeze™, and Biofuel.
Fermented protein that enhances food flavor and nutritional value.
Fermentation-based product for immune support in nutrition.
Fermented ingredient used for health and food applications.
Technology for preserving food through fermentation methods.
Fermentation-derived biofuel for sustainable energy use.
People of NextFerm
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of NextFerm
Investors in NextFerm
NextFerm has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for NextFerm
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NextFerm
Investment portfolio details for NextFerm
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NextFerm
Detailed financials for NextFerm
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nextferm Comparisons
Peer comparison for NextFerm
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NextFerm
NextFerm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nuevolution, Protalix BioTherapeutics, Lutris Pharma, Curesponse and Colbar LifeScience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug treatments for oncology and chronic inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Recombinant proteins are developed via a plant cell-based expression system.
|
|
| Locked | Locked | Locked |
Provider of anti-cancer therapy
|
|
| Locked | Locked | Locked |
Provider of a tissue culture system to analyze cancer growth and drug response
|
|
| Locked | Locked | Locked |
Collagen-based products for tissue regeneration and dental applications are developed.
|
|
| Locked | Locked | Locked |
Therapeutic products for ENT disorders are developed via FoamOtic technology.
|
Detailed competitors of NextFerm
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nextferm
Complete news archive for NextFerm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NextFerm
NextFerm was founded in 2013 and raised its 1st funding round 6 years after it was founded.
NextFerm is headquartered in Yokneam Illit, Israel. It is registered at Yokneam Illit, North District, Israel.
Annual revenue of NextFerm is $176.63K as on Dec 31, 2024.
The company was founded in 2013 and is located in Yokneam Illit, Israel. Non-GMO proprietary technology is utilized to develop improved microorganisms, focusing on yeast strains. Operations target the fermented ingredients sector, with solutions intended for food, dietary supplements, brewing, and animal feeds. Development efforts emphasize natural, non-genetically modified approaches to enhance microbial performance in these markets.
NextFerm's top competitors include Protalix BioTherapeutics, Lutris Pharma and Minovia Therapeutics.
NextFerm offers ProteVin™, Maximmune, AstaFerm®, NextFreeze™, and Biofuel.
NextFerm has 2 investors. Key investors include European Union, and EIC Fund.